Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QCCTW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
KM501
|
|||||
| Synonyms |
KM-501; KM 501; Recombinant anti-HER2 domain II and domain IV bispecific antibody-MMAE conjugate (Xuanzhu)
Click to Show/Hide
|
|||||
| Organization |
Xuanzhu Biopharmaceutical Co., Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 4 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Phase 1
Colorectal cancer [ICD11:2B91]
Phase 1
Gastric cancer [ICD11:2B72]
Phase 1
Lung cancer [ICD11:2C25]
Phase 1
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2 ECD2); Receptor tyrosine-protein kinase erbB-2 (HER2 ECD4)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Puchem SID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.